TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31558010
Drug: Proxelan® monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxelan® monotherapy (1 suppository at bedtime for 1 month)
Study: 29153295
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of saline (placebo group, n=48)
Study: 23245940
Drug: Calendula cream
Normalized name: CALENDULA
DrugBank: Calendula officinalis whole (DB14315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calendula cream
Study: 3900155
Drug: 3% topical
Normalized name: Triaz 3% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% topical minoxidil
Study: 29908389
Drug: Prediction tool
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction tool based on well-established risk factors (number of previous depressive episodes, residual depressive symptoms, severity of the last depressive episode, treatment)
Study: 26867060
Drug: Olmesartan 20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20-40 mg/Amlodipine 5-10 mg
Study: 26867060
Drug: Perindopril 4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4-8 mg/Amlodipine 5-10 mg
Study: 17874207
Drug: Atomoxetine (detailed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (detailed dosage not specified)
Study: 11939055
Drug: Selenium (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (1 mg sodium selenite, one time only)
Study: 19257818
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg) administered within 90 days after surgical repair of an osteoporotic hip fracture
Study: 11564611
Drug: Sham water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham water treatment units (WTUs).
Study: 7820981
Drug: Somatostatin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin, 100 micrograms subcutaneously at induction of anaesthesia and 8 hourly for 48 h
Study: 3078526
Drug: no analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: no analgesic supplement
Study: 29217669
Drug: 930 mg
Normalized name: PETROLATUM 930 mg in 1 g TOPICAL OINTMENT [Vitamins A and D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 930 mg choline/d
Study: 29217669
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg choline/d
Study: 19327776
Drug: On-treatment apolipoproteins
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment apolipoproteins A1 and B
Study: 19327776
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering treatment
Study: 19327776
Drug: Usual-dose simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual-dose simvastatin
Study: 27815148
Drug: Conditional cash
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditional cash transfer (monthly cash transfer conditional on school attendance ≥80% of school days per month)
Study: 23179896
Drug: Olmesartan 10
Normalized name: amlodipine-olmesartan 10 mg-20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 10 mg (up-titrated to 20 mg or 40 mg if needed)
Study: 23179896
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg (up-titrated to 5 mg or 10 mg if needed)
Study: 7617626
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus electrophoresis and UV blood irradiation (group 1)
Study: 8471816
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (group 2)
Study: 7617626
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (group 1)
Study: 2651492
Drug: PPA 75
Normalized name: Guaifenex PPA 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA 75 mg sustained release
Study: 2387651
Drug: PPA 25
Normalized name: APAP 650/CTM 4/PPA 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA 25 mg
Study: 30547316
Drug: F14512 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F14512 at dose level 10 mg/m2/day
Study: 28855568
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rGH)
Study: 21462059
Drug: Problem Solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Solving Therapy (PST), 1 to 8 sessions, 45 minutes each with a social worker
Study: 9495423
Drug: Dextromethorphan 30
Normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 30 mg
Study: 8346588
Drug: Salcatonin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salcatonin (any dose)
Study: 29718143
Drug: Colistin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin monotherapy and colistin-carbapenem combination EAT
Study: 29718143
Drug: Covering antibiotics
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covering antibiotics in propensity score-matched cohort (n = 338)
Study: 24344211
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (IFN‐α‐2b) 20 MIU/m(2) intravenously (IV) daily 5 days per week for 4 weeks (arm A)
Study: 22987303
Drug: Water (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (100 ml three times daily)
Study: 22987303
Drug: Coffee (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (100 ml three times daily)
Study: 8697293
Drug: Idazoxan (295
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (295 μg/kg)
Study: 6319151
Drug: ACTH 1‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 7.00 h in winter
Study: 6319151
Drug: ACTH 1‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 14.00 h in summer
Study: 25645168
Drug: Delayed-treatment waitlist
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment waitlist control group
Study: 22185621
Drug: ALC (alcoholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALC (alcoholic beverage containing 1 g·kg(‐1) body weight)
Study: 18510263
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (300 mg on day 1, 600 mg on day 2, 800 mg on day 3)
Study: 18510263
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (600 mg/day and 800 mg/day)
Study: 197444
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg i.m. ACTH4-10
Study: 22341380
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of hypertonic saline before airway clearance techniques
Study: 22341380
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of hypertonic saline during airway clearance techniques
Study: 22341380
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of hypertonic saline after airway clearance techniques
Study: 2328310
Drug: Half-strength formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-strength formulation (25 mg hydrochlorothiazide and 37.5 mg triamterene)
Study: 2328310
Drug: Full-strength formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-strength formulation (50 mg hydrochlorothiazide and 75 mg triamterene)
Study: 23127304
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point pressure release therapy (TPPRT)
Study: 14692928
Drug: Intralesional 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional 5-fluorouracil (5-FU) at weekly intervals for 12 weeks
Study: 10480608
Drug: Homeostasis model
Normalized name: CALCIUM HOMEOSTASIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeostasis model assessment (HOMA) using immunoreactive insulin
Study: 10480608
Drug: First-phase intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-phase intravenous glucose tolerance test (FSIVGTT)
Study: 8942885
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole applied to the lid margin in one eye
Study: 30167782
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day adjunctive raloxifene
Study: 25302927
Drug: GOS-supplemented formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS-supplemented formula (0.4 g/100 mL)
Study: 22689395
Drug: Topical microemulsion
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical microemulsion containing metronidazole
Study: 22689395
Drug: Commercial gel
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial gel product
Study: 30970056
Drug: Homeopathic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic therapy (including Berberis, Mercurius solubilis/Belladonna/Hepar sulphur, and Pyrogenium)
Study: 30970056
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (NSPT) + Homeopathic therapy
Study: 29974280
Drug: He-Ne laser
Normalized name: Ne
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: He-Ne laser and topical treatment
Study: 24699061
Drug: Losmapimod (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod (7.5 mg BD) for 6 weeks
Study: 19560322
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended-release (ER) 3, 6, 9, or 12 mg
Study: 17761460
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with dutasteride and tamsulosin
Study: 17761460
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with dutasteride
Study: 17761460
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with tamsulosin
Study: 6233150
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) 20 mg twice a day for 2 weeks, then aminoglutethimide (AG) 250 mg four times a day
Study: 16329060
Drug: Placebo (subconjunctival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subconjunctival injection), repeated after 2 months
Study: 12547661
Drug: 20-mcg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mcg oral contraceptive (OC)
Study: 2687691
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) 0.07 U/kg body weight, subcutaneously at bedtime
Study: 4629980
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (D.S.C.G.)
Study: 24326106
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg) guided by visual acuity stabilization criteria (group I)
Study: 24326106
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg) (group I)
Study: 24326106
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg) (group II)
Study: 24326106
Drug: Verteporfin photodynamic
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin photodynamic therapy (vPDT) (group III)
Study: 19664345
Drug: Oral mefenamic
Normalized name: meclofenamate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mefenamic acid and intramuscular meperidine (M&M)
Study: 12744480
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) at 0.05 mg/kg/day
Study: 1784030
Drug: Ribavirin therapy
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin therapy (200 mg four times a day)
Study: 7223696
Drug: Maternal education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal education program without nutritional supplement
Study: 31551213
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 50,000 IU weekly for 12 weeks
Study: 28396556
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for STIs during pregnancy (control group)
Study: 22287681
Drug: Dried distillers
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried distillers grains (DDG) supplement
Study: 8462537
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nicomorphine
Study: 8462537
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nicomorphine
Study: 8462537
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nicomorphine
Study: 7955553
Drug: Cortisol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol treatment
Study: 30828929
Drug: BioChaperone glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BioChaperone glargine lispro co-formulation (BC Combo)
Study: 28482406
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy (2-3 times)
Study: 25139116
Drug: Adjunctive systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive systemic amoxicillin and metronidazole (AMX-MET) during non-surgical treatment
Study: 25139116
Drug: Adjunctive systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive systemic amoxicillin and metronidazole (AMX-MET)
Study: 27607363
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus
Study: 15216449
Drug: Moxonidine (MOX)
DrugBank: Moxonidine (DB09242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (MOX) 0.2 - 0.6 mg/d
Study: 15216449
Drug: Metoprolol (MET)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (MET) 50 - 150 mg/d
Study: 137921
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide via metered-dose inhaler
Study: 21341919
Drug: Galantamine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (8 mg/day)
Study: 28876367
Drug: Xuezhikang (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (1200 mg/day, orally)
Study: 11228592
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (plain and enteric-coated formulations)
Study: 3055941
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin
Study: 11228592
Drug: First two
Approvals — FDA: no, EMA: no, PMDA: no
Description: First two months of treatment with low-dose aspirin
Study: 9334096
Drug: Intragastric balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric balloon implantation with intensive additional therapy by a dietitian (Group II)
Study: 9334096
Drug: Sham implantation
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham implantation with intensive additional therapy by a dietitian (Group III)
Study: 8487488
Drug: Theophylline 10
Normalized name: theophylline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 10 mg/kg and 20 mg/kg body weight
Study: 3326114
Drug: Zopiclone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 5.0 mg
Study: 3326114
Drug: Zopiclone 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 10.0 mg
Study: 31465720
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg)
Study: 26604649
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) therapy
Study: 21199833
Drug: Satavaptan 25
Normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan 25 mg/day
Study: 21199833
Drug: Satavaptan 50
Normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan 50 mg/day in CHF patients
Study: 21199833
Drug: Satavaptan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan therapy
Study: 17135984
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (FLX and CBT)
Study: 17603143
Drug: Daily step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily step count equating to 1-hr MVPA engagement
Study: 16089149
Drug: Angong niuhuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angong niuhuang pill (ANP)
Study: 7801868
Drug: Hirudin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (dose 3: 0.6 mg/kg bolus + 0.2 mg/kg/hour infusion)
Study: 7801868
Drug: Heparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5,000 U bolus + 1,000 U/hour infusion)
Study: 7801868
Drug: Hirudin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (dose 1)
Study: 7801868
Drug: Hirudin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (dose 2)
Study: 7801868
Drug: Hirudin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (dose 3)
Study: 2182703
Drug: Géméprost (vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Géméprost (vaginal suppository)
Study: 2182703
Drug: Sulprostone (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulprostone (intravenous infusion)
Study: 6154345
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with chemotherapy (bleomycin)
Study: 31974133
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy (295 patients)
Study: 11912355
Drug: Brimonidine twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine twice daily
Study: 9767193
Drug: Early antiplatelet
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiplatelet therapy
Study: 11351768
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin and dipyridamole
Study: 9767193
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antiplatelet agents (e.g. aspirin and clopidogrel)
Study: 1995788
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered deuterated pyridoxine (PN)
Study: 1995788
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered deuterated pyridoxine-5'-beta-D-glucoside (PN-glucoside)
Study: 1995788
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered pyridoxine-5'-beta-D-glucoside (PN-glucoside)
Study: 30642737
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 μg/day)
Study: 30700347
Drug: Chlorquinaldol‐promestriene vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorquinaldol‐promestriene vaginal tablets
Study: 30700347
Drug: Opin suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opin suppositories
Study: 24625322
Drug: PegIFNα (type
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα (type Y peginterferon α‐2b 90 μg, 135 μg, 180 μg and PegIFNα‐2a 180 μg, respectively, once a week) and ribavirin (< 75 kg, 1000 mg daily and ≥ 75 kg, 1200 mg daily) for 48 weeks
Study: 22388710
Drug: Corticosteroids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids plus pentoxifylline (prednisolone 40 mg/day plus pentoxifylline 400 mg thrice/day)
Study: 22388710
Drug: Corticosteroids alone
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids alone (prednisolone 40 mg/day)
Study: 11060935
Drug: Exposure with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure with counterconditioning (CC)
Study: 3718170
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment (double-blind placebo-controlled)
Study: 23946318
Drug: eletriptan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: eletriptan 80 mg (ELE-80)
Study: 21903737
Drug: Aclidinium 400
Normalized name: aclidinium 400 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium 400 μg bid
Study: 21903737
Drug: Tiotropium 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 8 μg once daily
Study: 1988514
Drug: Cefotaxime, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime, 2 g intravenously every 8 h (n = 16)
Study: 1988514
Drug: Ceftriaxone, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 2 g intravenously every 24 h (n = 17)
Study: 30856079
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (4000 IU daily for 2 months)
Study: 11144998
Drug: Tilidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine (1.5 mg/kg) administered on the day of dialysis
Study: 11144998
Drug: Tilidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine (1.5 mg/kg) administered on a day in the dialysis-free interval
Study: 9694404
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral melatonin administered at 12.30 hr